exemestane + placebo

Exemestane + placebo refers to a combination used in clinical trials where one group receives exemestane, an aromatase inhibitor, and the other group receives a placebo for comparison. Exemestane is a steroidal aromatase inactivator that irreversibly binds to and inactivates the aromatase enzyme, thereby reducing estrogen production. This reduction in estrogen slows or stops the growth of hormone-sensitive breast tumors, particularly in postmenopausal women with early or advanced breast cancer. Placebo is an inert substance with no therapeutic effect, used as a control to assess the efficacy and safety of exemestane[1][2][4][5].